Literature DB >> 23093635

The management of high-risk, locally advanced, prostate cancer radiation therapy.

Swetha Sridharan1, Padraig Warde.   

Abstract

Entities:  

Year:  2012        PMID： 23093635      PMCID： PMC3478343          DOI： 10.5489/cuaj.12260

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  12 in total

1.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

2.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Authors:  Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 5.  Controversies in prostate cancer radiotherapy: consensus development.

Authors:  H Lukka; P Warde; T Pickles; G Morton; M Brundage; L Souhami
Journal:  Can J Urol       Date:  2001-08       Impact factor: 1.344

6.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

7.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

8.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer.

Authors:  Michael J Zelefsky; Victor E Reuter; Zvi Fuks; Peter Scardino; Alison Shippy
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321
View more
  1 in total

1.  SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.

Authors:  Pilar Ma Samper Ots; Julia Luisa Muñoz García; Yesika Ríos Kavadoy; Ma Luz Couselo Paniagua; Elena Villafranca Iturre; Milagrosa Rodríguez Liñán; Ana María Pérez Casas; Rodrigo Muelas Soria; Blanca Ludeña Martínez; José López Torrecilla; Manuel Casaña Giner; Almudena Zapatero Laborda; Ma Magdalena Márquez García-Salazar
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.